Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Intranet
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Chugai In-Licenses Anti-TL1A Antibody RG6631 from Roche

Aug 7, 2024

Chugai announced that it has concluded a license agreement with Roche for Roche’s pipeline product RG6631, an anti-TL1A antibody, in late-stage product development for ulcerative colitis and Crohn’s disease.  Under the agreement, Chugai, which is 62% owned by Roche, obtains exclusive rights for the development and marketing of RG6631 in Japan and Roche receives an upfront fee and milestone payments.